Genomic technology could accelerate patient trials of new cancer drugs that are targeted to a tumor’s individual molecular profile.
Susan YoungFollow @twitterapi
I’m the biomedicine editor for MIT Technology Review. I look for stories where technology stands to improve human health or advance our understanding of the human condition.
I joined MIT Technology Review in March 2012 after a brief stint in the Washington, D.C., news bureau of the scientific journal Nature. Before I ventured to the East Coast, I spent several years in the San Francisco Bay Area as a doctoral student in molecular biology and one whirlwind year in science-writing boot camp in Santa Cruz.
In California, I wrote for the Stanford University press offices, the Multiple Sclerosis Discovery Forum, and the Salinas Californian newspaper. I grew up in a small town in eastern Texas, surrounded by bird song, rolling cattle fields, and lanky pine trees. When I’m not exploring health tech, you will probably find me cooking or giggling over an exceptional LOLcat.
Susan Young's Stories
A method for single-cell DNA analysis could provide a safer genetic screen for IVF.
Computer-controlled sedation could lighten the load for intensive-care staff and make the process safer for patients.
A startup will sift through “treasure troves” of data from failed trials to find abandoned Alzheimer’s drugs that might work for some patients.
The U.K. plans to sequence 100,000 National Health Service patients by 2017—in a bold push to be a genomic medicine leader.
Biotech startup Greenlight Biosciences has a cell-free approach to microbial chemical production.
Several gene therapies are or will soon be in late-stage human trials. One of them could be the first to get FDA approval for sale in the U.S.
Despite promising results in controlling neuronal activity, leaders in brain research still wrestle over turning their work into treatments.
Notre Dame researchers will test a concussion-detection app on nearly a thousand high school and youth football players.
Researchers are using smart helmets and imaging to study brain injury risk in young football players over a season.